TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA Cash Flow

Teva pharmaceutical industries ltd (TEVA)

CashFlow / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09	Dec'08	Dec'07
Operating activities:
Net income (loss)
-1,000	-2,472	-16,449	311	1,597	3,042	1,253	1,910	2,768	3,339	2,004	615	1,915
Depreciation and amortization
1,722	1,842	2,112	1,524	1,308	1,508	1,642	1,708	1,069	977	908	490	499
Impairment of long-lived assets
1,778	5,621	20,882	1,645	361	387	524	1,071	201	124	110	107	0
Net change in operating assets and liabilities
896	1,823	1,645	116	-967	-290	-968	-414	-594	205	-445	-76	854
Deferred income taxes – net and uncertain tax positions
-985	-837	-2,331	15	237	-226	-1,380	-690	-500	-199	-140	25	100
Purchase of research and development in process
-	-	-	-	-	-	-	-	-	-	-	-	0
Impairment of long lived assets
-	-	-	-	-	-	-	-	-	-	-	-	17
Stock-based compensation
119	155	133	124	117	95	64	82	91	80	54	63	67
Impairment of equity investment
-	-	-	-	124	0	-	-	-	-	-	-	-
Research and development in process
-	114	175	422	35	0	5	73	15	18	-	1,402	-
Financial Assets Write Off
-	-	-	-	-	-	-	-	-	-	-	369	-
Other items
-	-	-	14	-146	-24	-143	-7	-103	-57	-16	-84	-69
Net loss (gain) from sale of long-lived assets and investments
18	19	1,090	764	86	-1	-18	3	72	55	24	-	-
Other items
28	-135	13	-	-	-	0	-	-	-	-	-	-
Venezuela deconsolidation loss
-	-	383	-	0	-	-	-	-	-	-	-	-
Venezuela impairment of net monetary assets
-	-	42	603	-	0	-	-	-	-	-	-	-
Other-than-temporary impairment
-	-	-	-140	-736	-6	-	-	135	0	0	-	-
Net cash provided by operating activities
748	2,446	2,225	3,890	5,542	5,127	3,237	4,572	4,134	4,136	3,373	3,231	1,813
Investing activities:
Beneficial interest collected in exchange for securitized accounts receivables
1,487	1,735	1,282	1,335	-	-	-	-	-	-	-	-	-
Purchases of property, plant and equipment
525	651	874	901	772	929	1,031	1,104	1,053	710	719	681	542
Proceeds from sale of long lived assets
343	890	3,477	2,002	524	196	187	264	279	700	271	3,381	4,520
Purchases of investments and other assets
8	119	200	481	2,003	324	160	201	217	436	433	2,155	5,298
Other investing activities
-58	-11	282	212	5	30	104	93	49	58	35	-67	15
Acquisitions of subsidiaries, net of cash acquired
-	-	-43	36,148	3,309	363	39	0	6,561	4,951	0	4,749	18
Net cash provided by investing activities
1,355	1,866	3,446	-34,405	-5,565	-1,450	-1,147	-1,134	-7,601	-5,455	-916	-4,137	-1,353
Financing activities:
Redemption of convertible debentures
-	-	-	-	-	-	-	-	814	45	0	141	0
Repayment of senior notes and loans and other long-term liabilities
3,944	7,446	3,300	999	2,521	839	3,133	2,213	751	1,972	325	156	66
Proceeds from senior notes and loans, net of issuance costs
2,083	4,434	506	25,252	2,099	0	338	1,241	1,000	45	445	39	37
Proceeds From Senior Notes Net
-	-	-	-	-	-	-	3,783	5,723	2,492	0	0	-
Short term loans raised in connection with the acquisition of subsidiaries
-	-	-	-	-	-	-	-	-	-	-	1,750	0
Repayment of short term loans in connection with the acquisition of subsidiaries
-	-	-	-	-	-	-	-	-	-	-	0	0
Purchase of treasury shares
-	-	-	-	439	500	497	1,161	899	99	0	0	152
Net change in short-term debt
-2	-260	-1,683	1,998	29	-385	384	-2,492	-124	626	-2,002	30	-129
Purchase Of Non Controlling Interests In Connection With The Acquisition Of Barr
-	-	-	-	-	-	-	-	-	-	-	0	-
Excess tax benefit on options exercised
-	-	-	-	-	-	-	-	-	-	-	33	36
Other financing activities
-11	-57	-74	-169	-178	-9	23	5	5	14	19	-2	-1
Dividends paid on ordinary shares
-	12	901	1,303	1,155	1,156	1,089	855	800	668	529	387	299
Dividends paid on preferred shares
52	10	260	255	0	0	-	-	-	-	-	-	-
Proceeds from exercise of options by employees
-	-	-	35	388	514	91	14	71	180	169	192	212
Dividends paid to non-controlling interests
-	-	38	-	0	-	-	-	-	-	-	-	-
Proceeds from issuance of ordinary shares, net of issuance costs
-	-	-	329	3,291	0	-	-	-	-	-	-	-
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs
-	-	-	329	3,291	0	-	-	-	-	-	-	-
Purchase of Non-controlling Interest
-	-	-	-	-	-	-	-	75	0	42	-	0
Net cash used in financing activities
-1,926	-3,351	-5,750	25,217	4,805	-2,375	-3,883	-1,678	3,336	573	-2,265	1,358	-362
Translation adjustment on cash and cash equivalents
16	-142	54	-660	-62	-114	-48	23	-21	-1	-51	-86	58
Net change in cash and cash equivalents
193	819	-25	-5,958	4,720	1,188	-1,841	1,783	-152	-747	141	366	156
Non-cash financing and investing activities:
Conversion of mandatory convertible preferred shares into ordinary shares
-	3,880	-	-	-	-	-	-	-	-	-	-	-
Cash paid during the year for:
Cash paid during the year for Interest
840	815	795	290	243	294	331	297	230	186	191	154	179
Income taxes, net of refunds
552	420	106	341	802	675	1,298	614	276	354	-16	160	197
Net change in operating assets and liabilities:
Increase in sales reserves and allowances
-	-	-	-	-	-	-	-	-	-	-	854	-
Other current assets
-1,416	-1,437	658	-517	87	-36	106	-54	-240	51	137	-80	-
Trade payables, accrued expenses, employee-related obligations and other current liabilities
643	-500	-3,083	-695	-12	-614	378	-19	543	-295	295	545	-
Trade receivables net of sales reserves and allowances
-394	88	514	343	763	710	85	936	701	55	-150	-695	-
Increase in accounts receivable and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-316
Inventories
271	26	199	370	129	230	399	-511	-762	-124	-139	-548	-421
Inventory step-up
-	-	-67	-383	0	0	-	62	352	108	302	-	-
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information
-896	-1,823	-1,645	-116	967	290	968	414	594	-205	445	76	-
Increase (decrease) in sales reserves and allowances, accounts payable and accruals and other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-117
Decrease (increase) in working capital items
896	1,823	1,645	116	-967	-	-	-	-	-	-	-	854